logo

Denali Therapeutics Inc. (DNLI)



Trade DNLI now with
  Date
  Headline
1/8/2019 9:05:57 AM Denali Therapeutics Begins Dosing In Phase 1b Clinical Study Of DNL747 In Patients With ALS
1/8/2019 8:07:13 AM Cygnal Therapeutics Appoints Pearl Huang As CEO
12/10/2018 9:07:41 AM Denali Therapeutics Unveils First Patient Dosed In Phase 1b Study Of DNL201 For Parkinson’s Disease
11/1/2018 2:09:31 AM Denali Therapeutics, Sanofi To Develop RIPK1 Inhibitors For Treatment Of Neurological And Inflammatory Diseases
10/3/2018 9:07:04 AM CENTOGENE And Denali Announce Strategic Collaboration To Recruit LRRK2 Patients For Clinical Trials
8/7/2018 4:34:36 PM Denali Therapeutics Appoints Dana Andersen As Chief Technical And Manufacturing Officer
6/12/2018 6:00:53 AM AbCellera Announces Collaboration With Denali Therapeutics To Discover New Antibodies For Neurodegenerative Diseases
5/11/2018 8:08:15 AM Denali Therapeutics Q1 Net Loss $23.7 Mln Vs Loss $21.3 Mln Last Year
3/19/2018 8:15:18 AM Denali Therapeutics Q4 Net Loss $22.9 Mln Vs Net Loss $19.4 Mln Last Year
3/14/2018 7:07:43 AM Flagship Pioneering Launches Foghorn Therapeutics With Initial Capital Commitment Of $50 Mln
2/8/2018 9:04:20 AM Lonza Pharma & Biotech And Denali Therapeutics Announce Exclusive Strategic Partnership